Jove
Visualize
Contact Us

Related Experiment Videos

Advanced ovarian cancer.

M E van der Burg1

  • 1Department of Medical Oncology, University Hospital Rotterdam Dijkzigt, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary

Cytoreductive surgery is crucial for advanced ovarian cancer treatment, significantly improving survival rates. Optimal tumor removal, even in advanced stages, leads to longer progression-free and overall survival for patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule.

European journal of neurology·2013
Same author

[Adjuvant chemotherapy in patients operated on for early ovarian carcinoma].

Nederlands tijdschrift voor geneeskunde·2004
Same author

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.

British journal of cancer·2001
Same author

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer.

British journal of cancer·2001
Same author

Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study.

European journal of cancer (Oxford, England : 1990)·2001
Same author

Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study.

Annals of oncology : official journal of the European Society for Medical Oncology·2001
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Gynecologic Oncology
  • Surgical Oncology
  • Medical Oncology

Background:

  • Advanced ovarian cancer often presents with widespread abdominal metastasis, precluding complete primary tumor resection.
  • Multimodality treatment involving cytoreductive surgery and chemotherapy is the standard for advanced ovarian cancer.
  • Residual disease after surgery is a critical prognostic factor for patient survival.

Purpose of the Study:

  • To evaluate the impact of cytoreductive surgery on survival outcomes in advanced ovarian cancer.
  • To assess the benefit of achieving optimal tumor debulking (residual disease < 1 cm).
  • To determine the role of interval cytoreductive surgery in patients with suboptimal primary cytoreduction.

Main Methods:

  • Review of treatment approaches for advanced ovarian cancer, emphasizing cytoreductive surgery.
  • Analysis of prognostic significance of residual disease size after cytoreductive surgery.
  • Comparison of survival outcomes between patients undergoing different surgical strategies (primary vs. interval cytoreduction).

Main Results:

  • Optimal cytoreduction (< 1 cm residual disease) significantly doubles median survival compared to larger residual lesions.
  • Complete resection of macroscopic tumor offers the longest survival, with 2-year survival at 80% versus <22% for lesions >2 cm.
  • Interval cytoreductive surgery after chemotherapy improves survival in patients with suboptimal primary debulking, with a 5-year survival of 24% versus 13% for non-surgery patients.

Conclusions:

  • Cytoreductive surgery, particularly achieving optimal debulking, is a cornerstone in managing advanced ovarian cancer.
  • Interval cytoreductive surgery provides a significant survival benefit for patients with suboptimal primary cytoreduction, outweighing associated morbidity.
  • Aggressive surgical management, including interval debulking, improves progression-free and overall survival in advanced ovarian cancer, even in cases with unfavorable prognostic factors.

Related Experiment Videos